News
Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.
The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).
MCRB refocuses on microbiome therapies after VOWST divestiture. Lead candidate SER-155 shows promise in reducing infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback